916 related articles for article (PubMed ID: 11728801)
1. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system.
Nordberg J; Arnér ES
Free Radic Biol Med; 2001 Dec; 31(11):1287-312. PubMed ID: 11728801
[TBL] [Abstract][Full Text] [Related]
2. The thioredoxin antioxidant system.
Lu J; Holmgren A
Free Radic Biol Med; 2014 Jan; 66():75-87. PubMed ID: 23899494
[TBL] [Abstract][Full Text] [Related]
3. Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy.
Tonissen KF; Di Trapani G
Mol Nutr Food Res; 2009 Jan; 53(1):87-103. PubMed ID: 18979503
[TBL] [Abstract][Full Text] [Related]
4. A thioredoxin reductase and/or thioredoxin system-based mechanism for antioxidant effects of ambroxol.
Huang J; Xu J; Tian L; Zhong L
Biochimie; 2014 Feb; 97():92-103. PubMed ID: 24103200
[TBL] [Abstract][Full Text] [Related]
5. Mammalian thioredoxin reductase is irreversibly inhibited by dinitrohalobenzenes by alkylation of both the redox active selenocysteine and its neighboring cysteine residue.
Nordberg J; Zhong L; Holmgren A; Arnér ES
J Biol Chem; 1998 May; 273(18):10835-42. PubMed ID: 9556556
[TBL] [Abstract][Full Text] [Related]
6. Targeting the Thioredoxin System for Cancer Therapy.
Zhang J; Li X; Han X; Liu R; Fang J
Trends Pharmacol Sci; 2017 Sep; 38(9):794-808. PubMed ID: 28648527
[TBL] [Abstract][Full Text] [Related]
7. Effects of Mammalian Thioredoxin Reductase Inhibitors.
Arnér ESJ
Handb Exp Pharmacol; 2021; 264():289-309. PubMed ID: 32767140
[TBL] [Abstract][Full Text] [Related]
8. Molecular bases of thioredoxin and thioredoxin reductase-mediated prooxidant actions of (-)-epigallocatechin-3-gallate.
Zhang H; Cao D; Cui W; Ji M; Qian X; Zhong L
Free Radic Biol Med; 2010 Dec; 49(12):2010-8. PubMed ID: 20951799
[TBL] [Abstract][Full Text] [Related]
9. Thioredoxin system in cell death progression.
Lu J; Holmgren A
Antioxid Redox Signal; 2012 Dec; 17(12):1738-47. PubMed ID: 22530689
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in the development of thioredoxin reductase inhibitors as anticancer agents.
Liu Y; Li Y; Yu S; Zhao G
Curr Drug Targets; 2012 Oct; 13(11):1432-44. PubMed ID: 22876886
[TBL] [Abstract][Full Text] [Related]
11. Selenocysteine in mammalian thioredoxin reductase and application of ebselen as a therapeutic.
Ren X; Zou L; Lu J; Holmgren A
Free Radic Biol Med; 2018 Nov; 127():238-247. PubMed ID: 29807162
[TBL] [Abstract][Full Text] [Related]
12. Thioredoxin Cross-Linking by Nitrogen Mustard in Lung Epithelial Cells: Formation of Multimeric Thioredoxin/Thioredoxin Reductase Complexes and Inhibition of Disulfide Reduction.
Jan YH; Heck DE; Casillas RP; Laskin DL; Laskin JD
Chem Res Toxicol; 2015 Nov; 28(11):2091-103. PubMed ID: 26451472
[TBL] [Abstract][Full Text] [Related]
13. Indolin-2-one compounds targeting thioredoxin reductase as potential anticancer drug leads.
Kaminska KK; Bertrand HC; Tajima H; Stafford WC; Cheng Q; Chen W; Wells G; Arner ES; Chew EH
Oncotarget; 2016 Jun; 7(26):40233-40251. PubMed ID: 27244886
[TBL] [Abstract][Full Text] [Related]
14. The thioredoxin system in cancer.
Arnér ES; Holmgren A
Semin Cancer Biol; 2006 Dec; 16(6):420-6. PubMed ID: 17092741
[TBL] [Abstract][Full Text] [Related]
15. Activity assays of mammalian thioredoxin and thioredoxin reductase: fluorescent disulfide substrates, mechanisms, and use with tissue samples.
Montano SJ; Lu J; Gustafsson TN; Holmgren A
Anal Biochem; 2014 Mar; 449():139-46. PubMed ID: 24374250
[TBL] [Abstract][Full Text] [Related]
16. Mechanistic characterization of the thioredoxin system in the removal of hydrogen peroxide.
Pannala VR; Dash RK
Free Radic Biol Med; 2015 Jan; 78():42-55. PubMed ID: 25451645
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of thioredoxin and thioredoxin reductase by 4-hydroxy-2-nonenal in vitro and in vivo.
Fang J; Holmgren A
J Am Chem Soc; 2006 Feb; 128(6):1879-85. PubMed ID: 16464088
[TBL] [Abstract][Full Text] [Related]
18. [Selenium compounds in redox regulation of inflammation and apoptosis].
Rusetskaya NY; Fedotov IV; Koftina VA; Borodulin VB
Biomed Khim; 2019 Apr; 65(3):165-179. PubMed ID: 31258141
[TBL] [Abstract][Full Text] [Related]
19. Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase.
Hashemy SI; Ungerstedt JS; Zahedi Avval F; Holmgren A
J Biol Chem; 2006 Apr; 281(16):10691-7. PubMed ID: 16481328
[TBL] [Abstract][Full Text] [Related]
20. The thioredoxin system and cancer therapy: a review.
Mohammadi F; Soltani A; Ghahremanloo A; Javid H; Hashemy SI
Cancer Chemother Pharmacol; 2019 Nov; 84(5):925-935. PubMed ID: 31367788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
